Skip to main content
NCBI home page
Journal of Clinical and Experimental Hepatology logoLink to Journal of Clinical and Experimental Hepatology
. 2012 Jul 21;2(2):135–144. doi: 10.1016/S0973-6883(12)60102-9

Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease

Alita Mishra *, Zobair M Younossi *,**,*
PMCID: PMC3940561  PMID: 25755422

Abstract

Non-alcoholic fatty liver disease (NAFLD) is an important cause of liver disease burden across the world. By definition, although the histopathologic features of NAFLD are identical to that of alcoholic liver disease, its diagnosis requires absence of significant alcohol use and absence of other causes of chronic liver disease. We now know that NAFLD is not simply a disease of the Western world. It is manifested across the world, in varying rates, across gender, across varying ethnicities, and in its association with other host factors. In this review article, the definition of NAFLD, its spectrum, ranging from mild steatosis to hepatocellular injury and inflammation defined as non-alcoholic steatohepatitis (NASH) is discussed. Mild steatosis is generally a stable disease whereas NASH can be progressive. Based on current published literature, current incidence and prevalence of NAFLD and NASH are discussed. It is also accepted that these processes will continue to increase in prevalence with the rise of obesity, type II diabetes, and associated metabolic syndrome. Some of the risk factors have been well-established and are discussed. In addition, this review also presents emerging associations with other risk factors for NAFLD. Natural history of NAFLD is variable depending upon the histologic subtypes and other underlying comorbidities and is discussed in this review as well.

Keywords: NAFLD, NASH

Abbreviations: CVD, cardiovascular disease; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NHANES, National Health and Nutrition Examination Surveys; OSA, obstructive sleep apnea; PCOS, polycystic ovarian syndrome

Full Text

The Full Text of this article is available as a PDF (182.5 KB).

References

  • 1.Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. Asia-Pacific Working Party on NAFLD. J Gastroenterol Hepatol. 2007;22:778. doi: 10.1111/j.1440-1746.2007.05001.x. [DOI] [PubMed] [Google Scholar]
  • 2.Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474. doi: 10.1111/j.1572-0241.1999.01377.x. [DOI] [PubMed] [Google Scholar]
  • 3.American Gastroenterological Association (AGA) medical position Statement Non-alcoholic fatty liver disease. Gastroenterology. 2002;123:1702–1704. doi: 10.1053/gast.2002.36569. [DOI] [PubMed] [Google Scholar]
  • 4.Whalley S, Puvanachandra P, Desia A, Kennedy H. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med. 2007;7:119–124. doi: 10.7861/clinmedicine.7-2-119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Suzuki A, Angulo P, Lymp J. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64–71. doi: 10.1002/hep.20543. [DOI] [PubMed] [Google Scholar]
  • 6.Hamaguchi M, Kojima T, Takeda N. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med. 2005;143:722–728. doi: 10.7326/0003-4819-143-10-200511150-00009. [DOI] [PubMed] [Google Scholar]
  • 7.Browning JD, Szczepaniak LS, Dobbins R. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395. doi: 10.1002/hep.20466. [DOI] [PubMed] [Google Scholar]
  • 8.Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol. 2009;50:797–804. doi: 10.1016/j.jhep.2008.11.017. [DOI] [PubMed] [Google Scholar]
  • 9.Lee JY, Kim KM, Lee SG. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol. 2007;47:239–244. doi: 10.1016/j.jhep.2007.02.007. [DOI] [PubMed] [Google Scholar]
  • 10.Marcos A, Fisher RA, Ham JM. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation. 2000;69:2410–2415. doi: 10.1097/00007890-200006150-00034. [DOI] [PubMed] [Google Scholar]
  • 11.Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis. 2007;11:1–16. doi: 10.1016/j.cld.2007.02.009. [DOI] [PubMed] [Google Scholar]
  • 12.Kopec KL, Burns D. Nonalcoholic fatty liver disease. a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565–576. doi: 10.1177/0884533611419668. [DOI] [PubMed] [Google Scholar]
  • 13.Ong JP, Elariny H, Collantes R. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310–315. doi: 10.1381/0960892053576820. [DOI] [PubMed] [Google Scholar]
  • 14.Hamaguchi M, Kojima T, Takeda N. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–1584. doi: 10.3748/wjg.v13.i10.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 doi: 10.1002/hep.25762. [DOI] [PubMed] [Google Scholar]
  • 16.Younossi ZM, Stepanova M, Afendy M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clinical Gastroenterol Hepatol. 2011;9:524–530. doi: 10.1016/j.cgh.2011.03.020. [DOI] [PubMed] [Google Scholar]
  • 17.Fan JG, Zhu J, Li XJ. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol. 2005;43:508–514. doi: 10.1016/j.jhep.2005.02.042. [DOI] [PubMed] [Google Scholar]
  • 18.Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71–79. doi: 10.1053/gast.2003.50004. [DOI] [PubMed] [Google Scholar]
  • 19.Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55:607–613. doi: 10.1159/000235677. [DOI] [PubMed] [Google Scholar]
  • 20.Chen CH, Huang MH, Yang JC. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol. 2007;22:1482–1489. doi: 10.1111/j.1440-1746.2006.04615.x. [DOI] [PubMed] [Google Scholar]
  • 21.Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49:608–612. doi: 10.1016/j.jhep.2008.06.018. [DOI] [PubMed] [Google Scholar]
  • 22.Hossain N, Afendy A, Stepanova M. Independent predictors of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1224–1229. doi: 10.1016/j.cgh.2009.06.007. [DOI] [PubMed] [Google Scholar]
  • 23.Kagansky N, Levy S, Keter D. Non-alcoholic fatty liver disease-a common and benign finding in octogenarian patients. Liver Int. 2004;24:588–594. doi: 10.1111/j.1478-3231.2004.0969.x. [DOI] [PubMed] [Google Scholar]
  • 24.Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285. doi: 10.1111/j.1365-2036.2011.04724.x. [DOI] [PubMed] [Google Scholar]
  • 25.Reid A. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710–723. doi: 10.1053/gast.2001.27126. [DOI] [PubMed] [Google Scholar]
  • 26.Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008;9:616–622. doi: 10.1631/jzus.B0720016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg. 2006;16:1351. doi: 10.1381/096089206778663715. [DOI] [PubMed] [Google Scholar]
  • 28.Williams CD, Stengel J, Asike MI. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124. doi: 10.1053/j.gastro.2010.09.038. [DOI] [PubMed] [Google Scholar]
  • 29.Wagenknecht LE, Scherzinger AL, Stamm ER. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity. 2009;17:1240–1246. doi: 10.1038/oby.2009.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Romeo S, Kozlitina J, Xing C. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465. doi: 10.1038/ng.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Valenti L, Al-Serri A, Daly AK. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1209–1217. doi: 10.1002/hep.23622. [DOI] [PubMed] [Google Scholar]
  • 32.He S, McPhaul C, Li JZ. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010;285:6706–6715. doi: 10.1074/jbc.M109.064501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Petersen KF, Dufour S, Hariri A. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082–1089. doi: 10.1056/NEJMoa0907295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Speliotes EK, Yerges-Armstrong LM, Wu J. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7:e1001324. doi: 10.1371/journal.pgen.1001324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–119. doi: 10.1111/j.1478-3231.2008.01718.x. [DOI] [PubMed] [Google Scholar]
  • 36.Prashanth M, Ganesh HK, Vima MV. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57:205–210. [PubMed] [Google Scholar]
  • 37.Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899–905. doi: 10.1503/cmaj.045232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Younossi ZM, Gramlich T, Matteoni CA. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262–265. doi: 10.1016/s1542-3565(04)00014-x. [DOI] [PubMed] [Google Scholar]
  • 39.Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410–1415. doi: 10.1136/gut.2010.213553. [DOI] [PubMed] [Google Scholar]
  • 40.Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419. doi: 10.1016/s0016-5085(99)70506-8. [DOI] [PubMed] [Google Scholar]
  • 41.Angelico F, Del Ben M, Conti R. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18:588–594. doi: 10.1046/j.1440-1746.2003.02958.x. [DOI] [PubMed] [Google Scholar]
  • 42.Boza C, Riquelme A, Ibañez L. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–1153. doi: 10.1381/0960892055002347. [DOI] [PubMed] [Google Scholar]
  • 43.Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40:475–483. doi: 10.1002/hep.20323. [DOI] [PubMed] [Google Scholar]
  • 44.Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–606. doi: 10.1016/j.jhep.2006.06.013. [DOI] [PubMed] [Google Scholar]
  • 45.Colicchio P, Tarantino G, del Genio F. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab. 2005;49:289–295. doi: 10.1159/000087295. [DOI] [PubMed] [Google Scholar]
  • 46.Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138:1240–1244. doi: 10.1001/archsurg.138.11.1240. [DOI] [PubMed] [Google Scholar]
  • 47.Bellentani S, Saccoccio G, Masutti F. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117. doi: 10.7326/0003-4819-132-2-200001180-00004. [DOI] [PubMed] [Google Scholar]
  • 48.Dolce CJ, Russo M, Keller JE. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery. Surg Obes Relat Dis. 2009;5:323–328. doi: 10.1016/j.soard.2008.12.008. [DOI] [PubMed] [Google Scholar]
  • 49.Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408. doi: 10.1111/j.1572-0241.2006.01041.x. [DOI] [PubMed] [Google Scholar]
  • 50.Harnois F, Msika S, Sabaté JM. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2006;16:183–188. doi: 10.1381/096089206775565122. [DOI] [PubMed] [Google Scholar]
  • 51.Spaulding L, Trainer T, Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg. 2003;13:347–349. doi: 10.1381/096089203765887633. [DOI] [PubMed] [Google Scholar]
  • 52.Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:s99–s112. doi: 10.1002/hep.20973. [DOI] [PubMed] [Google Scholar]
  • 53.Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223–1236. doi: 10.1056/NEJMra041536. [DOI] [PubMed] [Google Scholar]
  • 54.Setji TL, Brown AJ. Polycystic ovary syndrome: diagnosis and treatment. Am J Med. 2007;120:128–132. doi: 10.1016/j.amjmed.2006.06.029. [DOI] [PubMed] [Google Scholar]
  • 55.Welt CK, Gudmundsson JA, Arason G. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab. 2006;91:4842–4848. doi: 10.1210/jc.2006-1327. [DOI] [PubMed] [Google Scholar]
  • 56.Cerda C, Perez-Ayuso RM, Riquelme A. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47:412–417. doi: 10.1016/j.jhep.2007.04.012. [DOI] [PubMed] [Google Scholar]
  • 57.Hossain N, Stepanova M, Afendy A. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS) Scand J Gastroenterol. 2011;46:479–484. doi: 10.3109/00365521.2010.539251. [DOI] [PubMed] [Google Scholar]
  • 58.Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or causal link? World J Gastroenterol. 2010;16:4243–4252. doi: 10.3748/wjg.v16.i34.4243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev. 2005;9:211–224. doi: 10.1016/j.smrv.2005.01.006. [DOI] [PubMed] [Google Scholar]
  • 60.Keijer J, van Schothorst EM. Adipose tissue failure and mitochondria as a possible target for improvement by bioactive food components. Curr Opin Lipidol. 2008;19:4–10. doi: 10.1097/MOL.0b013e3282f39f95. [DOI] [PubMed] [Google Scholar]
  • 61.Mishra P, Nugent C, Afendy A. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int. 2008;28:1080–1086. doi: 10.1111/j.1478-3231.2008.01822.x. [DOI] [PubMed] [Google Scholar]
  • 62.Requarth JA, Burchard KW, Colacchio TA. Long term morbidity following jejunoileal bypass: the continuing potential need for surgical reversal. Arch Surg. 1995;130:318–325. doi: 10.1001/archsurg.1995.01430030088018. [DOI] [PubMed] [Google Scholar]
  • 63.Grundy SM, Brewere HB, Jr, Celleman JI, Smith SC, Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart Lung and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation. 2004;109:433–438. doi: 10.1161/01.CIR.0000111245.75752.C6. [DOI] [PubMed] [Google Scholar]
  • 64.Adams LA, Lymp JF, St Sauver J. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121. doi: 10.1053/j.gastro.2005.04.014. [DOI] [PubMed] [Google Scholar]
  • 65.Soderberg C, Stal P, Askling J. Decreased survival of subjects with elevated liver function tests during a 28 year follow-up. Hepatology. 2010;51:595–602. doi: 10.1002/hep.23314. [DOI] [PubMed] [Google Scholar]
  • 66.Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649. doi: 10.3109/07853890.2010.518623. [DOI] [PubMed] [Google Scholar]
  • 67.Lebovics E, Rubin J. Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. Diabetes Metab Res Rev. 2011;27:419–424. doi: 10.1002/dmrr.1198. [DOI] [PubMed] [Google Scholar]
  • 68.Pais R, Pascale A, Fedchuck L, Charlotte F, Poynard T, Ratziu V. Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. Clin Res Hepatol Gastroenterol. 2011;35:23–28. doi: 10.1016/j.gcb.2010.06.004. [DOI] [PubMed] [Google Scholar]
  • 69.Hernaez R. Genetic factors associated with the presence and progression of nonalcoholic fatty liver disease: a narrative review. Gastroenterol Hepatol. 2011 doi: 10.1016/j.gastrohep.2011.08.002. [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  • 70.Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438. [PubMed] [Google Scholar]
  • 71.Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–1719. [PubMed] [Google Scholar]
  • 72.Wong VW, Wong GL, Choi PC. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974. doi: 10.1136/gut.2009.205088. [DOI] [PubMed] [Google Scholar]
  • 73.Younossi ZM, Stepanova M, Rafiq N. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53:1874–1882. doi: 10.1002/hep.24268. [DOI] [PubMed] [Google Scholar]
  • 74.Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol. 1989;20:594–598. doi: 10.1016/0046-8177(89)90249-9. [DOI] [PubMed] [Google Scholar]
  • 75.Powell EE, Cooksley WG, Hanson R. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80. doi: 10.1002/hep.1840110114. [DOI] [PubMed] [Google Scholar]
  • 76.Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371–379. doi: 10.1016/j.jhep.2009.03.019. [DOI] [PubMed] [Google Scholar]
  • 77.Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042–2047. doi: 10.1111/j.1572-0241.2003.07659.x. [DOI] [PubMed] [Google Scholar]
  • 78.Sanyal AJ, Banas C, Sargent C. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43:682–689. doi: 10.1002/hep.21103. [DOI] [PubMed] [Google Scholar]
  • 79.Rafiq N, Bai C, Fang Y. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–238. doi: 10.1016/j.cgh.2008.11.005. [DOI] [PubMed] [Google Scholar]
  • 80.Ratziu V, Bonyhay L, Di Martino V. Survival, liver failure, and hepatocellular carcinoma is obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485–1493. doi: 10.1053/jhep.2002.33324. [DOI] [PubMed] [Google Scholar]
  • 81.Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236. doi: 10.1002/hep.20933. [DOI] [PubMed] [Google Scholar]
  • 82.Yatsuji S, Hashimoto E, Tobari M. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastoenterol Hepatol. 2009;24:248–254. doi: 10.1111/j.1440-1746.2008.05640.x. [DOI] [PubMed] [Google Scholar]
  • 83.Bhagat V, Mindikoglu AL, Nudo CG. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl. 2009;15:1814–1820. doi: 10.1002/lt.21927. [DOI] [PubMed] [Google Scholar]
  • 84.Yalamanchili K, Saadeh S, Klintmalm GB. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic liver disease. Liver Transpl. 2010;16:431–439. doi: 10.1002/lt.22004. [DOI] [PubMed] [Google Scholar]
  • 85.Targher G, Bertolini L, Rodella S. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–2121. doi: 10.2337/dc07-0349. [DOI] [PubMed] [Google Scholar]
  • 86.Kim CH, Park JY, Lee KU. Fatty liver is an independent risk factor for the development of Type II diabetes in Korean adults. Diabetes Med. 2008;25:476–481. doi: 10.1111/j.1464-5491.2008.02410.x. [DOI] [PubMed] [Google Scholar]
  • 87.Yamada T, Fukatsu M, Suzuki S. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health check-up. J Gastroenterol Hepatol. 2010;25:352–356. doi: 10.1111/j.1440-1746.2009.05998.x. [DOI] [PubMed] [Google Scholar]
  • 88.Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol. 1995;104:23–31. doi: 10.1093/ajcp/104.1.23. [DOI] [PubMed] [Google Scholar]
  • 89.Mottin CC, Moretto M, Padoin AV. Histological behavior of hepatic steatosis in morbidly obese patients after weight lass induced by bariatric surgery. Obes Surg. 2005;15:788–793. doi: 10.1381/0960892054222830. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical and Experimental Hepatology are provided here courtesy of Elsevier

RESOURCES